Business
Exelixis Announces Results From COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Multiple Advanced Solid Tumor Types
– Data from three cohorts of phase 1b COSMIC-021 trial to be presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program
About this update from Exelixis, Inc.
[{"type":"text","content":"\n– Data from three cohorts of phase 1b COSMIC-021 trial to be presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20) –\n\n\n– 27% objective response rate seen in immune checkpoint inhibitor-pretreated non-small cell lung cancer cohort 7 –\n\n\n– Phase 3 pivotal trials planned for advanced non-small cell lung cancer and metastatic castration-resistant prostate cancer –\n\n ALAMEDA, Calif.--(BUSINESS WIRE)--\nExelixis, Inc. (NASDAQ: EXEL) today announced phase 1b clinical trial results for the combination of cabozantinib (CABOMETYX®) and atezolizumab (TECENTRIQ®) in patients with locally advanced or metastatic solid tumors. The data from three expansion cohorts of the COSMIC-021 trial will be presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20). Results from the non-small cell lung cancer (NSCLC) and the metastatic castration-resistant prostate cancer (CRPC) cohorts will be presented as posters, and results from the urothelial carcinoma (UC) cohort will be presented as a poster discussion; all three presentations will be available on demand for ASCO20 registrants beginning Friday, May 29 at 8:00 a.m. ET.\n\n\nNSCLC Expansion Cohort (abstract 9610):\n\n\nInitial results from the NSCLC expansion cohort (cohort 7) will be presented by Joel Neal, M.D., Ph.D., Associate Professor of Medicine – Oncology at the Stanford University School of Medicine, one of the lead trial investigators. The analysis included 30 patients who had received prior therapy with immune checkpoint inhibitors, and 87% of patients had received prior chemotherapy. Fifty percent of patients received the cabozantinib and atezolizumab combination as their second line of therapy and 50% as their third line of therapy. At the time of enrollment in the study, the best response to prior immune checkpoint inhibitor therapy was a partial response in 3 (10%) patients, stable disease in 7 (23%) patients, progressive disease in 14 (47%) patients and unknown in 5 (17%) patients.\n\n\nAt a median follow-up of 12.1 months, the investigator-assessed confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1, the trial’s primary endpoint, was 27%, and the disease control rate was 83%. Median progression-free survival (PFS) was 4.2 months (95% co...